CKBR-12 is a Natural Ibogaine Derivative Medicine and Health Product (NHP) currently under evaluation as an anti-Parkinson medication. Developed by Genesis Parkinson’s Research Center a division of Genesis Parkinson’s Institute Inc., CKBR-12 is manufactured in Mexico under GMP conditions in a GMP compliant facility. CKBR-12 was employed in an experimental protocol in the treatment of non-motor and motor dysfunction symptoms of Parkinson disease (PD).
The trial, which encompassed a holistic patient-driven view of care, demonstrated a rapid amelioration or elimination of both motor and non-motor symptoms of PD, leading to an overall improvement of patient health-related quality of life (HRQOL). These unexpected, promising and previously unreported results gave rise to the filing of a US and PCT provisional patent, Rapid Method for Reducing Motor and Non-Motor Symptoms of Parkinson’s disease. Preliminary results indicate an amelioration of both non-motor symptoms and motor symptoms within two (2) weeks of the onset of the CKBR-12 treatment.
A reduced level of bradykinesia and rigidity was reported, which expressed itself in a tremendous improved postural stability gait, and speech. An elimination or tremors and of excess saliva and drooling was also noted. The absence of depression and restored cognitive abilities were two of the most promising findings during this 30 day treatment with CKBR-12. Data was captured using Patient-Reported Outcome (PRO) tools and video to evaluate HRQOL.
These observations provide support for the hypothesis that CKBR-12 represents a novel means of ameliorating and eliminating non-motor and motor PD symptoms and improving the overall HRQOL of Parkinson patients. The unexpected findings of CKBR-12 on the severity and occurrence of multiple NMS require further clinical research, as these observed effects could decrease the growing social disability of PD patients significantly and consequently ease the burden on the socio-economic costs for healthcare.
Comments are closed